Bioconjugates, ADCs & Chemistry

Supporting your candidate ranking and lead selection process, we determine the optimal design of linker payload architecture and profiling in a series of in silico, in vitro and ex vivo activity and safety assessments. We use a matrix evaluation and a developability approach to streamline the development, scale, and manufacture of your linker payloads.

Leverage our experience in the synthesis of payloads, linkers, and payload-linker chemical intermediate constructs to enable the rapid generation of structure activity relationships (SAR) of various linker combinations with your new payloads. Accelerating and de-risking the development and manufacture of your next-generation therapies, Abzena’s integrated approach supports the lifecycle of ADC discovery and development including the design and synthesis of payload-linker constructs for ADCs and bioconjugates. We identify the most suitable linker for your ADC profile.

We design and deliver tailored solutions for small molecule intermediates including high potency chemistry, payloads, linkers, payload-linker chemical intermediates, bioconjugation and Antibody Drug Conjugates (ADCs). We support partners with the design, synthesis and manufacture of payloads and payload-linker constructs for ADC and bioconjugation. To support lead drug candidate selection, we utilize our expertise in identifying and mapping the appropriate design space for the development of your complex ADCs.

Through the application of our developability assessments, we identify and de-risk your clinical candidates for development and ensure stage-specific milestones are met.

To meet your program goals, we develop novel and improve existing synthetic routes for complex chemicals, cytotoxins, payloads, linkers, HPAPI, biopolymers, and nanoparticles. We design, evaluate, and execute state-of-the-art synthetic strategies to deliver quality molecules with chiral integrity.

We offer product development and formulation programs to accelerate your timelines by leveraging our comprehensive in-house capabilities, technologies, and knowledge to deliver processes tailored to your molecule of interest.

We ensure the purity and integrity of your products by offering an extensive range of capabilities in the Analytical Method Development (AMD) and QC departments.

Our approach to Analytics and Bioassays focuses on giving you all of the rapid insight needed to help make informed decisions earlier during your drug development journey.

Our formulation development experience allows us to align your drug to your preferred target product profile (TPP) with a comprehensive range of packages including stable liquid and lyophilized formulations.

We can ensure seamless scale up through to commercial launch. That’s because our process development, optimization and manufacturing teams collaborate together to develop quality, commercially viable processes.

Supporting the robust scaling of your project from clinical through to commercial scale, we are dedicated to quality excellence, delivering small molecule intermediates including high potency chemistry, payloads, linkers, payload-linker chemical intermediates, bioconjugation and Antibody Drug Conjugates (ADCs).

Simplifying your project and de-risking technology transfer, we deliver specialized, integrated services across the lifecycle of your products.